X4 Pharmaceuticals Inc (NASDAQ: XFOR) on Monday, soared 32.27% from the previous trading day, before settling in for the closing price of $0.40. Within the past 52 weeks, XFOR’s price has moved between $0.26 and $1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.00% over the last five years. The company achieved an average annual earnings per share of 77.49%. With a float of $117.21 million, this company’s outstanding shares have now reached $168.51 million.
The firm has a total of 93 workers. Let’s measure their productivity. In terms of profitability, gross margin is 85.2%, operating margin of -618.81%, and the pretax margin is -398.61%.
X4 Pharmaceuticals Inc (XFOR) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of X4 Pharmaceuticals Inc is 31.28%, while institutional ownership is 35.58%. The most recent insider transaction that took place on Nov 15 ’24, was worth 12,583. In this transaction President and CEO of this company sold 31,897 shares at a rate of $0.39, taking the stock ownership to the 993,919 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Officer proposed sale 31,897 for $0.41, making the entire transaction worth $13,078.
X4 Pharmaceuticals Inc (XFOR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 77.49% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
X4 Pharmaceuticals Inc (XFOR) is currently performing well based on its current performance indicators. A quick ratio of 4.80 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 82.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Analysing the last 5-days average volume posted by the [X4 Pharmaceuticals Inc, XFOR], we can find that recorded value of 2.38 million was better than the volume posted last year of 2.35 million. As of the previous 9 days, the stock’s Stochastic %D was 84.84%. Additionally, its Average True Range was 0.06.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 41.84%, which indicates a significant decrease from 94.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 137.80% in the past 14 days, which was lower than the 161.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4884, while its 200-day Moving Average is $0.8112. Now, the first resistance to watch is $0.5772. This is followed by the second major resistance level at $0.6264. The third major resistance level sits at $0.7131. If the price goes on to break the first support level at $0.4413, it is likely to go to the next support level at $0.3546. Should the price break the second support level, the third support level stands at $0.3054.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
Market capitalization of the company is 92.38 million based on 170,546K outstanding shares. Right now, sales total 0 K and income totals -101,170 K. The company made 560 K in profit during its latest quarter, and -36,700 K in sales during its previous quarter.
